MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors, highlighting the need for an individualized, molecular subtyping profile in early stage breast cancer diagnosing for patients.
The findings suggest that tumor development can span the entire lifetime of an individual, so the mutations that initiate cancer progression may arise decades before diagnosis.
The FDA today issued draft guidance detailing its plans for regulating laboratory-developed tests (LDTs) that it deems as “high-risk” along the lines of Class...
The GenomeAsia 100K Consortium released the results of their examination of the genomes of 1,739 people from 219 different population groups in 64 countries across Asia. The findings shed light on the history of human migration and will potentially improve clinicians’ ability to diagnose and treat disease.
The platform comprises a cartridge-housed microfluidic chip that carries out isothermal amplification of viral nucleic acids from nasal swab samples, which are then detected using the smartphone camera.
Washington University School of Medicine researchers show 89% accuracy using MRI versus roughly 70% for APOE 4 gene testing
The Cascadion SM Clinical Analyzer eyes a ripening market for mass spec in clinical labs, with commercial availability planned for 2018
The genetic testing and associated services will help the 13,800 Fund members better understand their genetic risk for hereditary cancers, heart disease, and medication response.
A study, funded by the Movember Foundation and conducted by scientists at The Institute of Cancer Research (ICR) in London, has revealed several genetic...
Genomic technologies enabling relatively simple, rapid, and costeffective high-throughput testing of RNA-based multiplexed signatures in blood samples would greatly facilitate wide-scale adoption of molecular diagnostic tests in clinical medicine. Tests like...